Guangdong Yili Group Pharmaceutical Holding Co., Ltd. is a high-tech privately-run pharmaceutical enterprise mainly engaged in new drugs R&D, planting and extraction of Chinese medicinal materials, production, sales and logistics of medicine, and preparation of bio-organic fertilizers.
The company has a registered capital of 110 million RMB, with a total area of more than 200 mu and factory premises covering 135,000 square meters. With its strong technical workforce, the company has over 1000 employees, 30% of which are technical professionals holding senior and intermediate professional titles.
The company’s predecessor was Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. No.4 Factory. In December 2002, Guangdong Yili Pharmaceutical Co., Ltd. was established after completion of the system reform. Guangdong Yili Pharmaceutical Group Co., Ltd. was established after transformation into the group was finalized in 2006 and 2008. In 2008, Guangzhou Yili Group Pharmaceutical Co., Ltd. was established as the wholly-funded subsidiary under Guangzhou Yili Group Co., Ltd. In 2014, Guangdong Yili Group Co., Ltd. confirmed Guangdong Yili Group Pharmaceutical Co., Ltd. as the main participant in its prospective listing process, and completed asset restructuring of three subsidiaries under Guangdong Yili Group Co., Ltd.: Guangdong Yili Medical Co., Ltd., Guangdong Green Technology Development Co., Ltd. and Sihui Yili Logistics Co., Ltd., so that these companies would form the wholly-funded subsidiary under Guangzhou Yili Group Co., Ltd. In September 2015, Guangdong Yili Group Pharmaceutical Co., Ltd. was renamed Guangdong Yili Group Pharmaceutical Holding Co., Ltd. The company currently has seven subsidiaries.
The company has the core advantages and marketing features to guarantee its participation in market competition. With resources that include capital, brand, variety and management information, the company teamed with several enterprises with famous products in the marketing process and successfully developed an operation model consisting of “intensive integration of famous and high-quality Chinese patent medicine.”
The company engages in close technical cooperation with several renowned pharmaceutical scientific research institutes and colleges and universities and pharmaceutical development institutions. With its sophisticated technologies, the company transformed high-tech achievements into tangible productivity to sharpen its core competitive edge.
The company is committed to developing a pollution-free industry chain. With pharmaceutical industry at its core, the company continues to explore related industries in its construction of a larger, stronger pharmaceutical industry.